ConductScience.org, home

Paper26106962

Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment.

Wu JT and 3 others. Clinics (Sao Paulo), 2015. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. Papers, record 26106962. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26106962

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment.
PubMed
Journal
Clinics (Sao Paulo)
PubMed
Year
2015
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.34
iCite
Revised in PubMed
2024-06-07
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wu JTJiun-Ting
2Chiu CTChien-Tung
3Wei YFYu-Feng
4Lai YFYung-Fa

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antitubercular AgentsMajor topic
Tuberculosis, PulmonaryMajor topic
Adult
Aged
Aged, 80 and over
Bilirubin
Directly Observed Therapy
Drug Administration Schedule
Drug Combinations
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Hyperuricemia
Male
Middle Aged
Prospective Studies
Radiography
Skin Diseases
Sputum
Treatment Outcome
Vision Disorders

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00979290Adverse Reactions and Efficacy of Fixed-dose Combination Anti-tuberculosis (TB) DrugsDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
12114029[A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment].Rev Mal Respir1990https://conductscience.org/library/papers/2114029PubMed
221239028Trends of mycobacterial clinical isolates in Taiwan.Trans R Soc Trop Med Hyg2011https://conductscience.org/library/papers/21239028PubMed
3324964Adverse reactions to rifampicin in antituberculosis regimens.J Antimicrob Chemother1977https://conductscience.org/library/papers/324964PubMed
42604291Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy.Am Rev Respir Dis1989https://conductscience.org/library/papers/2604291PubMed
521077990Increased prevalence of primary drug-resistant pulmonary tuberculosis in immunocompromised patients.Respirology2011https://conductscience.org/library/papers/21077990PubMed
611567729Private practitioners and public health: weak links in tuberculosis control.Lancet2001https://conductscience.org/library/papers/11567729PubMed
712475151Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.Int J Tuberc Lung Dis2002https://conductscience.org/library/papers/12475151PubMed
821486974Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.JAMA2011https://conductscience.org/library/papers/21486974PubMed
912588714American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.Am J Respir Crit Care Med2003https://conductscience.org/library/papers/12588714PubMed
109562106How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.Int J Tuberc Lung Dis1998https://conductscience.org/library/papers/9562106PubMed
1119460254Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis.Int J Tuberc Lung Dis2009https://conductscience.org/library/papers/19460254PubMed
1215182145Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin.Int J Tuberc Lung Dis2004https://conductscience.org/library/papers/15182145PubMed
1319251545A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature.J Formos Med Assoc2009https://conductscience.org/library/papers/19251545PubMed
1411217670The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis.Bull World Health Organ2001https://conductscience.org/library/papers/11217670PubMed
1510091877
Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
Int J Tuberc Lung Dis1999https://conductscience.org/library/papers/10091877PubMed
1615599473Guidelines for chemotherapy of tuberculosis in Taiwan.J Microbiol Immunol Infect2004https://conductscience.org/library/papers/15599473PubMed
1723314904Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis.Eur Respir J2013https://conductscience.org/library/papers/23314904PubMed
182648511[Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis].Rev Mal Respir1989https://conductscience.org/library/papers/2648511PubMed
1920688288Drug resistance pattern of mycobacterium tuberculosis complex at a medical center in central Taiwan, 2003-2007.J Microbiol Immunol Infect2010https://conductscience.org/library/papers/20688288PubMed
207755232Fixed-dose combinations of antituberculous medications to prevent drug resistance.Ann Intern Med1995https://conductscience.org/library/papers/7755232PubMed

See all 26 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
32476718Health technology assessment of fixed-dose combination regimen in treatment of newly diagnosed smear-positive pulmonary tuberculosis: A meta-analysis.Med J Armed Forces India2020https://conductscience.org/library/papers/32476718PubMed
30908689Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review.Br J Clin Pharmacol2019https://conductscience.org/library/papers/30908689PubMed
30089476
Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar.
BMC Infect Dis2018https://conductscience.org/library/papers/30089476PubMed
28538778
Estimated rates of recurrence, cure, and treatment abandonment in patients with pulmonary tuberculosis treated with a -four-drug fixed-dose combination regimen at a tertiary health care facility in the city of Rio de Janeiro, Brazil.
J Bras Pneumol2017https://conductscience.org/library/papers/28538778PubMed
28152986Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.BMC Infect Dis2017https://conductscience.org/library/papers/28152986PubMed
27186634Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis.Cochrane Database Syst Rev2016https://conductscience.org/library/papers/27186634PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
SLC17A526503PubTator's text mininghttps://conductscience.org/library/genes/26503

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26106962

GET https://conductscience.org/api/papers/v1/26106962/references?page=2